Free Trial
NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Price, News & Analysis

Century Therapeutics logo
$0.51 +0.02 (+3.16%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$0.51 0.00 (-0.06%)
As of 10/3/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Century Therapeutics Stock (NASDAQ:IPSC)

Advanced

Key Stats

Today's Range
$0.48
$0.52
50-Day Range
$0.47
$0.64
52-Week Range
$0.34
$1.83
Volume
700,148 shs
Average Volume
394,142 shs
Market Capitalization
$44.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75
Consensus Rating
Moderate Buy

Company Overview

Century Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

IPSC MarketRank™: 

Century Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 576th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Century Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Century Therapeutics has a consensus price target of $3.75, representing about 630.6% upside from its current price of $0.51.

  • Amount of Analyst Coverage

    Century Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Century Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Century Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Century Therapeutics is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Century Therapeutics is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Century Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Century Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.57% of the float of Century Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Century Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Century Therapeutics has recently decreased by 6.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Century Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Century Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.57% of the float of Century Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Century Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Century Therapeutics has recently decreased by 6.41%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $645.00 in company stock.

    • Percentage Held by Insiders

      Only 5.00% of the stock of Century Therapeutics is held by insiders.

    • Percentage Held by Institutions

      50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Century Therapeutics' insider trading history.
    Receive IPSC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    IPSC Stock News Headlines

    An $8 trillion-dollar discovery 17,000 ft underwater
    A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
    Century Reports Flat Loss in Fiscal Q2
    See More Headlines

    IPSC Stock Analysis - Frequently Asked Questions

    Century Therapeutics' stock was trading at $1.01 at the beginning of 2025. Since then, IPSC stock has decreased by 49.2% and is now trading at $0.5133.

    Century Therapeutics, Inc. (NASDAQ:IPSC) announced its earnings results on Thursday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.38). Century Therapeutics had a negative net margin of 19.10% and a negative trailing twelve-month return on equity of 11.53%.

    Century Therapeutics (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

    Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

    Company Calendar

    Last Earnings
    8/14/2025
    Today
    10/05/2025
    Next Earnings (Estimated)
    11/04/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:IPSC
    CIK
    1850119
    Fax
    N/A
    Employees
    170
    Year Founded
    2018

    Price Target and Rating

    High Price Target
    $6.00
    Low Price Target
    $2.00
    Potential Upside/Downside
    +630.6%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.60
    Research Coverage
    5 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($0.29)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$126.57 million
    Net Margins
    -19.10%
    Pretax Margin
    -18.85%
    Return on Equity
    -11.53%
    Return on Assets
    -6.94%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    10.72
    Quick Ratio
    10.72

    Sales & Book Value

    Annual Sales
    $6.59 million
    Price / Sales
    6.73
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $1.90 per share
    Price / Book
    0.27

    Miscellaneous

    Outstanding Shares
    86,390,000
    Free Float
    82,070,000
    Market Cap
    $44.34 million
    Optionable
    Optionable
    Beta
    1.78

    Social Links

    Options Trading Made Easy - Download Now Cover

    Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

    Get This Free Report

    This page (NASDAQ:IPSC) was last updated on 10/5/2025 by MarketBeat.com Staff
    From Our Partners